Tarik DEMİR, Ezgi COBAN, Murat ARAZ, Altay ALİYEV, Mesut SEKER, Haci Mehmet TURK

Prognostic impact of primary tumor location on survival in metastatic colorectal cancer patients: A single center experience

Primary tumor location (PTL) is associated with very different outcomes in patients with metastatic colorectal cancer (mCRC). Clinical trials suggest that right side tumor location is an indicator of poor prognosis for patients with mCRC. The relationship between the primary tumor location and clinicopathological features such as; gender, family history, carcinoembryonic antigen (CEA) level, metastasectomy status, the presence of a mucinous component, RAS mutation status, and overall survival (OS) were evaluated. A total of 253 patients (203 left-sided, 50 right-sided) were included in the study. Median OS time for patients with metastatic right sided colon tumors were 19 (15.2-22.7) months, and OS for left sided colon tumors were 35 (29.5-40.4) months. The left-sided colon group’s OS time was significantly higher than the right-sided colon group (p

PDF

___

1. Missiaglia E, Jacobs B, D’Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25:1995-2001.

2. Ahmed S, Johnson K, Ahmed O, et al. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis. 2014;29:1031-42.

3. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol. 2005;12:900-9.

4. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350-6.

5. Bendardaf R, Buhmeida A, Hilska M et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 2008;28:3865-70.

6. Lee GH, Malietzis G, Askari A, et al. Is right-sided colon cancer different from left-sided colorectal cancer? - A systematic review. Eur J Surg Oncol. 2015;41:300-8.

7. Tejpar S, Stintzing S, Ciardiello F et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3:194-201.

8. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17.

9. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011-9.

10. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-75.

11. Douillard JY, Siena S, Cassidy J et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer: Ann Oncol. 2014;25:1346-55.

12. Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus, at al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240-7.

13. N. Boeckx, R. Koukakis, K. Op de Beeck, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies: Annals of Oncology. 2017;28:1862–8.

14. Julian Walter Holch, Ingrid Ricard, Sebastian Stintzing et al. The relevance of primary tumor location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials: European Journal of Cancer. 2017;70:87-98.

15. Fotios Loupakis, Dongyun Yang, Linda Yau, et al. Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Natl Cancer Inst. 2015;107.

16. Dalyong Kim, Sun Young Kim, Ji Sung Lee, et al. Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer: BMC Gastroenterology. 2017;17:121.

17. Shahid Ahmed, Punam Pahwa, Le Duc et al. Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer: Clin Colorectal Cancer. 2018;17:201-6.

18. Timothy J. Price, Carol Beeke, Shahid Ullah et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?: Cancer. 2015;121:830-5.